Welcome to our dedicated page for CG Oncology SEC filings (Ticker: CGON), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The CG Oncology, Inc. (NASDAQ: CGON) SEC filings page provides access to the company’s official U.S. Securities and Exchange Commission disclosures related to its late-stage clinical biopharmaceutical activities in non-muscle invasive bladder cancer (NMIBC). As a public company, CG Oncology files periodic and current reports that describe its financial condition, governance changes, and key clinical and regulatory milestones for its investigational intravesical oncolytic immunotherapy, cretostimogene grenadenorepvec.
Among the most relevant documents for CGON are current reports on Form 8-K, which the company uses to report material events. Recent 8-K filings have detailed board of director changes, including the appointment of a new director and the resignation of another, as well as transitions in the principal financial and accounting officer role. Other 8-Ks reference press releases announcing quarterly financial results, updated BOND-003 Cohort C data in high-risk BCG-unresponsive NMIBC, and corporate presentations at healthcare conferences.
Investors also look to CG Oncology’s quarterly and annual reports (Forms 10-Q and 10-K, when available) for broader context on its clinical development program, including the BOND-003 and PIVOT-006 Phase 3 trials and the CORE-008 Phase 2 study, as well as information about its Expanded Access Program in North America. These filings typically discuss risk factors, research and development expenses, and other elements that shape the company’s outlook as a late-stage clinical biopharmaceutical issuer.
On Stock Titan, CGON filings are updated as they are posted to EDGAR, and AI-powered tools can help summarize lengthy documents such as earnings-related 8-K exhibits or future 10-K and 10-Q reports. Users can also review governance and compensation disclosures embedded in 8-K items related to director appointments and executive transitions, and track how these developments align with CG Oncology’s efforts to advance cretostimogene through the regulatory process.
CG Oncology director James Mulay reported an exercise-and-sale transaction in the company’s common stock. On April 17, 2026, he exercised options to acquire 15,600 shares of common stock at $36.63 per share, then sold the same 15,600 shares in an open-market transaction at a weighted average price of $73.01 per share.
The filing states these sales were made under a pre-arranged Rule 10b5-1 trading plan adopted on June 6, 2025, indicating they were scheduled in advance rather than timed discretionarily. After these transactions, Mulay reported holding no shares of common stock or related director stock options directly.
James Mule filed a Form 144 proposing the sale of 17,564 shares of Common stock on 04/17/2026. The sale is listed as an Exercise of Stock Options with cash proceeds. The filing also shows prior 10b5-1 sales of 1,964 shares on 03/16/2026 for $124,714.
CG Oncology, Inc. reported that President and COO Bellete Ambaw received a grant of employee stock options. The award covers 107,508 options to buy common stock at an exercise price of $67.68 per share, expiring on April 14, 2036.
According to the footnote, 1/48th of the options vest monthly after the April 15, 2026 vesting commencement date, contingent on Ambaw’s continuous service. Following this grant, Ambaw directly holds 107,508 derivative securities linked to CG Oncology common stock.
CG Oncology, Inc. reported that Chief Medical Officer Kasturi Vijay received an employee stock option grant for 79,216 shares of common stock. The option has an exercise price of $67.68 per share, expires on April 14, 2036, and represents a compensation-related award rather than an open-market trade.
These options vest over time: 1/48 of the shares vest monthly after April 15, 2026, as long as Vijay continues providing service to the company. Following this grant, Vijay holds derivative rights to acquire 79,216 shares through this option.
CG Oncology, Inc. reported that officer Joshua F. Patterson received an employee stock option grant covering 45,266 shares of common stock. The option has an exercise price of $67.68 per share and expires on April 14, 2036.
According to the terms, 1/48th of the option vests each month after the vesting commencement date of April 15, 2026, as long as Patterson remains in continuous service with the company. This is a compensation-related equity award rather than an open-market stock purchase or sale.
CG Oncology, Inc. reported that Chief Financial Officer James M. Detore received an employee stock option grant covering 90,574 shares of common stock. The option has an exercise price of $67.68 per share and expires on April 14, 2036.
According to the vesting terms, the option vests over four years starting on April 15, 2026, with 25% of the shares vesting 12 months after that date and the remaining 75% vesting in 36 equal monthly installments over the following three years. This is a compensation-related award rather than an open-market purchase.
CG Oncology, Inc. reported that Chief Executive Officer Arthur Kuan received a grant of employee stock options covering 271,600 shares of common stock. The options have an exercise price of $67.68 per share and expire on April 14, 2036.
According to the award terms, 1/48th of the shares subject to the option vest monthly following April 15, 2026, as long as Kuan continues to provide services to the company through each vesting date. After this grant, he holds 271,600 derivative securities linked to common stock.
CG Oncology, Inc. has appointed Jim DeTore as its Chief Financial Officer, effective April 13, 2026, after he served as interim principal financial and accounting officer since November 2025. He brings prior CFO experience from multiple biotechnology companies, including Neurogastrx and Bluebird Bio.
Under his new employment agreement, DeTore will receive a base salary of $520,000 and an annual target bonus equal to 45% of salary. He is also being granted stock options with a target value of $4 million and a performance stock unit award with a target value of $1 million, both granted on April 15, 2026 and vesting over time and upon achieving specific commercial and cash flow milestones.
The agreement provides severance protections, including salary, bonus, COBRA-related benefits, and equity vesting acceleration if he is terminated without cause, with enhanced benefits if this occurs in connection with a change in control.
The Vanguard Group amended its Schedule 13G/A to report zero beneficial ownership of CG Oncology Inc. common stock. The filing explains an internal realignment effective January 12, 2026 under SEC Release No. 34-39538, after which certain Vanguard subsidiaries report holdings separately. The form is signed on 03/26/2026.
CG Oncology director James Mulay exercised stock options for 1,964 shares of Common Stock and sold the same number of shares in pre-planned trades. He exercised Director Stock Options for 654 shares at $3.72 and 1,310 shares at $12.59 per share, then sold 654 and 1,310 shares at $63.50 per share in open-market transactions. The sales were made under a Rule 10b5-1 trading plan adopted on June 6, 2025, indicating these trades were scheduled in advance rather than timed discretionarily.